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Background & Objective: Breast cancer is the most prevalent 
invasive cancer and the second major cause of cancer deaths in women 
after lung cancer. Awareness of the symptoms and need for screening 
are essential to reducing the risk of breast cancer. Despite its high 
incidence rate, the molecular biology of breast cancer remains 
unknown. The present study aimed to investigate the expression of 
non-coding RNA (lncRNA) NAV2-AS2, which is located on 
chromosome 11p15.1 as a member of neuron navigator gene family, in 
breast cancer. 
Materials and Methods: Total RNA was extracted from 40 tumors 
and 40 normal tissues using the RNA extraction kit. After cDNA 
synthesis using Takara cDNA synthesis kit, the expressional analysis 
of the AS2 gene was evaluated by real-time polymerase chain reaction 
(PCR). 
Results: AS2 was overexpressed in 45% of the tumor samples 
compared to the normal samples. Statistical analysis showed 
significant correlations between AS2 gene expression, lobular 
carcinoma, and histology grade in situ breast cancer. In other words, 
the increased expression of this non-coding RNA was associated with 
a higher risk of lobular carcinoma and disease grade.  
Conclusion: According to the results, NAV2-AS2 genes may be 
effective in the tumor genesis and progression of breast cancer. 
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Introduction 
After puberty, a woman's breast consists of 
fat, connective tissue, and thousands of 
lobules, which are the minuscule glands that 
produce milk for breastfeeding. Very small 
tubes, or ducts, carry the milk toward the 
nipple. In cancer, the cells in the body 
multiply uncontrollably, and the subsequent 
excessive cell growth causes cancer. Breast 
cancer usually begins in the inner lining of 
milk ducts or the lobules that supply them 
with milk. From there, the disease could 
spread to the other parts of the body [1].  
Breast cancer is a complicated, 
heterogeneous disease that is molecularly 
categorized into four distinct subtypes, 
including luminal A, luminal B, HER2 
overexpression, and triple-negative breast 
cancer [2]. Based on these classifications,  
various therapies are performed on breast 
cancer patients. However, the metastatic 
potential may vary even in the similar 
subtypes of cancer. To improve the 
prognosis of breast cancer, it is crucial to 
identify new, efficient therapeutic targets for 
effective disease management. 
Long non-coding RNAs (lncRNAs) have 
been introduced as the deregulated factors in 
various cancers [3]. LncRNAs, which are 
longer than 200 bases and contain more than 
90% of the genome, are involved in different 
cell mechanisms. Growing evidence has 
suggested the function of lncRNAs in 
various cancer features, such as cell 
proliferation, metastasis, and apoptosis. 
Increased knowledge of the role of lncRNAs 
in physiological and pathological processes  
 
has highlighted their potential use as 
diagnostic biomarkers, as well as targets for 
the novel therapeutic approaches toward 
malignancies [4]. Although some studies 
have defined different lncRNAs as tumor 
suppressors or oncogenes in tumorigenesis, 
it is of utmost importance to investigate the 
role of other lncRNAs in different cancers. 
Neuron navigator 2 (NAV2) is one of the 
three members of the neuron navigator 
family, which is involved in neurogenesis 
and tumorigenesis [5]. NAV2 protein 
contains various functional domains, 
including the calponin homology (CH) 
domain, four coiled-coil (CC) domains, a 
cytoskeletal interacting domain (CSID), and 
an AAA domain [6]. The functional 
domains are involved in various cellular 
processes, including protein degradation, 
signal transduction, regulation of gene 
expression, membrane fusion, microtubule 
dynamics, and cell migration. Previous 
findings have confirmed that NAV2 affects 
cell migration through adjusting microtubule 
dynamics [7, 8], leading to basement 
membrane breakdown, formation of actin 
stress fiber, and metal matrix protease 
secretion. Furthermore, NAV2 regulates the 
cytoskeleton, which affects cell-cell and 
cell-matrix adhesion, facilitating tumor cell 
invasion and metastasis [8, 9]. Previous 
studies have denoted that NAV2 plays a key 
role in cancer and metastasis through cofilin, 
which is an essential regulator of actin 
dynamics and the targeting factors in 
APC/Wnt/β-catenin signaling pathway. On 
the other hand, few studies have assessed 
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NAV2 Antisense RNA2 (NAV2-AS2), which 
is located in the minus strand of the NAV2 
gene.The present study aimed to investigate 
the mRNA expression level of NAV2-AS2 
lncRNA in breast cancer and elucidate their 
correlation with the indices of poor 
prognosis in breast cancer patients. 
Materials and Methods 
In this study, tumor and paired normal 
tissues were obtained from 40 breast cancer 
patients by Iran National Tumor Bank, 
which has been founded by Cancer Institute 
of Tehran University of Medical Sciences 
for cancer research. The demographic 
characteristics were based on the seventh 
edition of Union International Cancer TNM 
classification guidelines. The study was 
performed after obtaining informed consent 
from all the recruited patients. 
RNA Extraction, cDNA Synthesis, and 
qRT-PCR 
Using TriPure RNA extraction reagent 
(Roche, Nutley, NJ), RNA was extracted 
from all the tissues. The quality of RNA was 
assessed by gel electrophoresis and 
nanodrop. PrimeScript First Strand cDNA 
Synthesis Kit (Takara, Japan) was used for 
cDNA synthesis. To assess the mRNA 
expression level, specific primers were 
designed using Primer3 online software, and 
cDNA was amplified by qRT-PCR using the 
SYBR green method (SYBR green mix, 
YTA, Iran) on CFX96 Touch™ Real-Time 
PCR Detection System (Bio-Rad, 
Philadelphia, PA, USA).  
The following optimal thermal conditions 
were applied: 10 minutes at the temperature 
of 95°C, 45 cycles of 15 seconds at the 
temperature of 95°C, 30 seconds at the 
temperature of 60°C, and 45 seconds at the 
temperature of 72°C. Data of real-time 
polymerase chain reaction (PCR) were 
normalized using glyceraldehyde 3-
phosphate dehydrogenase (Table 1) [Liu L-
L et al., 2015], and the ΔΔCT method was 
applied for the fold change evaluation of the 
gene expression in the tumor samples and 
comparison with the normal tissues. All the 
reactions were performed in triplicate. 
Statistical Analysis 
Data analysis was performed in SPSS 
version 23 (SPSS, Chicago, IL) using χ2, 
Fisher’s exact test, independent sample t-
test, and analysis of variance (ANOVA) to 
determine the correlations of mRNA 
expression level with the clinical and 
pathological data. P-value of less than 0.05 
was considered statistically significant. 
Results 
Study Population and Clinical 
Demographic Data 
In total, 40 female patients with breast 
cancer, who had received no treatment, were 
enrolled in the study. Mean age of the 
patients was 49.55±13.03 years. The size of 
tumor samples was 1.5-10 centimeters. 
Clinical and pathological features of the 
patients are presented in Table 2. 
Correlation of the Overexpression of AS2 
with Histology Grade and Lobular 
Carcinoma in Situ Histology in Breast 
Cancer  
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The relative and comparative real-time PCR 
on AS2 expression showed the 
overexpression of this lncRNA in breast 
cancer. Mean AS2 gene expression was 
1.1±0.9 in the breast cancer tissues, and the 
gene was significantly overexpressed in 
approximately 45% of the tumor samples 
(18 out of 40 samples). Increased level of 
AS2 mRNA expression was significantly 
correlated with various indices of poor 
prognosis, including lobular carcinoma in 
situ histology (P=0.014) and histology grade 
(P=0.023).  
Discussion and Conclusion  
Breast cancer is a highly heterogeneous 
disease, and selecting the appropriate 
treatment to improve its prognosis is rather 
complex [10]. The molecular investigations 
regarding the initiation, progression, and 
metastasis of cancer have successfully 
elucidated the mechanism of this disease, as 
well as the most effective target therapies 
[11]. LncRNAs have been assessed 
extensively after demonstrating the different 
regulating roles of non-coding RNA 
HOTAIR in cancer. The correlation between 
lncRNA and various indices of prognosis 
could definitely lead to finding the main 
regulators of the master genes in cancer and 
targeted therapies. In the present study, the 
expression level of NAV2-AS2 was 
evaluated to verify their possible role in 
breast cancer progression. According to the 
findings, the overexpression of AS2 was 
significantly associated with lobular 
carcinoma in situ histology and histology 
grade. 
NAV2 is located on chromosome 11p15.1 
and is identified with other aliases, such as 
UNC53H2, POMFIL2, HELAD1, and 
RAINB1 [12]. This gene was initially 
considered to be an all-trans retinoic acid-
responsive gene in neuritis outgrowth [6]. 
Recently, the overexpression of NAV2 has 
been highlighted in 16 out of 20 colon 
cancers [13]. Examination of the molecular 
mechanism of NAV2 overexpression has 
indicated its role in the migration and 
invasion of colon cancer through F-actin 
polymerization and the SSH1L/cofilin-1 
pathway [14]. Moreover, several studies 
have confirmed the role of cytoskeleton in 
epithelial-mesenchymal transition and 
cancer [15-17]. In this cohort study, we 
analyzed the NAV2-AS2 lncRNA, and the 
overexpression of NAV2-AS2 was observed 
in the breast cancer patients. 
Previous studies have reported variable 
lncRNAs overexpression in breast cancer. 
For instance, Deng J et al. (2017) claimed 
that the overexpression of HOTAIR (a well-
known lncRNA) is a key regulator of the 
main mechanisms of cancer stem cells, 
including proliferation, colony formation, 
invasion, and self-renewal capacity, in 
breast cancer [18]. Furthermore, the 
overexpression of RNA-H19 has been 
shown to promote breast cancer cell 
clonogenicity and migration [19]. In another 
study, Huang NS et al. (2016) stated that the 
metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1) as the lncRNA was 
up-regulated in breast cancer [20]. In line 
with these studies, our findings indicated 
that NAV2-AS2 was overexpressed in breast 
cancer in correlation with the histology 
grade of the disease. In our cohort, 64% of 
the patients had grade II breast cancer with 
the overexpression of NAV2-AS2. 
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Intriguingly, the overexpression of this 
lncRNA was statistically correlated with 
lobular carcinoma in situ (LCIS) histology; 
as a result, we predicted that NAV2-AS2 
could be a novel lncRNA to be used as a 
diagnostic biomarker for breast cancer since 
LCIS could indicate the increased risk of 
cancer in the future. Such extrapolations 
require further in-vitro and in-vivo 
investigations in order to determine the 
exact mechanisms of how the deregulation 
of antisense RNA could alter the expression 
of NAV2 and the possible tumorigenic role 
of this perturbation.  
In conclusion, our study demonstrated a 
novel lncRNA in breast cancer, the 
overexpression of which has a significant 
association with various indices and 
carcinogenesis of this cancer. In addition, 
this lncRNA could be a novel biomarker to 
diagnosis breast cancer in the early stages 
considering its significant correlation with 
LCIS.  
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Table 1. Primer Sequences Used for qRT-PCR 
Gene Forward Primer Reverse Primer 
GAPDH GGAAGGTGAAGGTCGGAGTCA GTCATTGATGGCAACAATATCCACT 
AS2 ATTCTTCTTGCCCGACGTG ATTCCCTGTGGTCTGGTGATG 
Table 2. Clinical and Pathological Data of Patients 
  N NAV2-AS2 Expression 
Age (year) >50 20 .402 
 <50 20  
Tumor Size 0-2 2 0.677 
 2-5 28  
 5< 8  
Pathological (T) Tx 2 0.34 
 T1a 2  
 T2 25  
 T3 9  
 T4 2  
Pathological (N) Nx 4 0.20 
 NOITC 2  
 NO(NOC) 12  
 N1 13  
 N2 7  
 N3 2  
Clinical Metastasis Mx 3 0.378 
 M0 35  
 M1 1  
 M Pending 1  
Histology Grade I 7 0.023⃰ 
 II 18  
 III 8  
 X 7  
Lobular Carcinoma in Situ Histology   0.014⃰ 
*The clinical factors (age, tumor size, tumor type, tumor classification) show the tumor invasion of the 
surrounding tissues, classification of the lymph nodes that demonstrate the spread of cancer to the 
surrounding tissues, classification of metastasis, probability of the dissemination of metastases to other 
areas, and histology grade and lobular carcinoma in terms of number and their association with NAV2-
AS2 expression. 
